Physician profile
Peter Dux
NPI 1851338917
$3,517.01
in general payments reported to CMS, 2019-2025
27 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 95% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2023: $388 · 2024: $1,443 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $611.69 | 2024-2025 | Airsupra, Breztri |
| Abbott Laboratories | $368.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $316.48 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $288.90 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Phathom Pharmaceuticals, INC. | $280.33 | 2024 | Voquezna |
| Pfizer INC. | $200.51 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $189.42 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $162.89 | 2023-2024 | Lumryz |
| Lilly USA, LLC | $147.64 | 2023-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $138.94 | 2019 | |
| Boston Scientific Corporation | $126.03 | 2023-2024 | Wavewriter Alpha Prime 16, Freelink, Click |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.98 | 2023-2025 | Jardiance |
| Abbvie INC. | $102.24 | 2023-2024 | Qulipta, Ubrelvy, Vraylar |
| Astellas Pharma US INC | $57.79 | 2024 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $41.01 | 2024-2025 | |
| Springworks Therapeutics, INC. | $30.52 | 2025 | Gomekli |
| Dexcom, INC. | $30.05 | 2024-2025 | Dexcom G6 Transmitter |
| Cvrx, INC. | $26.88 | 2024 | Barostim Neo System |
| Sanofi Pasteur INC. | $26.87 | 2025 | |
| Inspire Medical Systems, INC. | $24.74 | 2025 | Inspire |
| Corcept Therapeutics | $20.25 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $19.58 | 2023 | Shingrix, Arexvy |
| Lundbeck LLC | $19.24 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $17.70 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $16.39 | 2024 | Camzyos |
| Scilex Pharmaceuticals INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.